283 related articles for article (PubMed ID: 22732017)
1. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Cope S; Donohue JF; Jansen JP; Kraemer M; Capkun-Niggli G; Baldwin M; Buckley F; Ellis A; Jones P
Respir Res; 2013 Oct; 14(1):100. PubMed ID: 24093477
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
Cope S; Capkun-Niggli G; Gale R; Lassen C; Owen R; Ouwens MJ; Bergman G; Jansen JP
Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
5. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
Cope S; Capkun-Niggli G; Gale R; Jardim JR; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2011; 6():329-44. PubMed ID: 21697997
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Cope S; Kraemer M; Zhang J; Capkun-Niggli G; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2012; 7():415-20. PubMed ID: 22848154
[TBL] [Abstract][Full Text] [Related]
8. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
9. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
Karner C; Cates CJ
Cochrane Database Syst Rev; 2012 Apr; 4(4):CD008989. PubMed ID: 22513969
[TBL] [Abstract][Full Text] [Related]
10. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Jones PW; Mahler DA; Gale R; Owen R; Kramer B
Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Huisman EL; Cockle SM; Ismaila AS; Karabis A; Punekar YS
Int J Chron Obstruct Pulmon Dis; 2015; 10():1863-81. PubMed ID: 26392761
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
[TBL] [Abstract][Full Text] [Related]
15. Ten years of tiotropium: clinical impact and patient perspectives.
Yohannes AM; Connolly MJ; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2013; 8():117-25. PubMed ID: 23515335
[TBL] [Abstract][Full Text] [Related]
16. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
Mahler DA; Buhl R; Lawrence D; McBryan D
Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
[TBL] [Abstract][Full Text] [Related]
20. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Worth H; Chung KF; Felser JM; Hu H; Rueegg P
Respir Med; 2011 Apr; 105(4):571-9. PubMed ID: 21227674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]